Compared with paclitaxel or carboplatin alone, the combination of CSF-1R signaling antagonists with paclitaxel or carboplatin exhibited enhanced antitumor efficacy and suppressed metastasis in preclinical BC models [223]. The gene discussed is CSF1R; the disease is breast cancer.